SlideShare a Scribd company logo
In this issue:
Endotoxin Limits
Technical Services Department
Calendar
Volume 13, No.2
pfiJLAL
UPDATE®
June 1995
Dear LAL User,
There are now definite signs that summer will soon arrive on
Cape Cod. The horseshoe crabs have appeared once again in the
shallow bays in preparation for spawning and our laboratory is
bursting with activity. Although the amount ofour harvestfrom
season to season is difficult to predict, the last two years have seen
recordyields ofLAL and we hope for a repeat this year. Even with
increased sales, these good harvests have resulted in an excellent
inventory ofPyrotell'" (all sensitivities), Pyrotell'"-T, and
Pyrochrome"
For our European customers, the changeoverfrom afragmented
distribution system to direct supply and service from Associates of
Cape Cod International, Inc. is complete. Our two European offices
are located in Walldorf(near Frankfurt) Germany, and Liverpool,
England. Our general managers, Dr. Peter Weidner (ACCI-Europe
in Germany), and Tony Coyle (ACCI-UK) have extensive experience
with all aspects ofLAL and endotoxin testing. In addition to our
expanded technical services, ACCI-Europe can provide multilingual
help for our clients in France, Italy, and Spain.
The Tyros™ for Windows" software for the LAL-5000 is now
firmly established in the marketplace. Ifyou are using the LAL-5000
and have not yet switched to Tyros™, I strongly urge you to
consider doing so. It is much easier andfaster to use and has a host
ofadvancedfeatures.
As you can see, it is not all vacation and retirement on Cape Cod.
Even so, please feel free to make our summer even busier! Our
technical service team, Laurie, Keith, and Carmen are ready to
answer your technical questions, as are other personnel, including
Drs. Dawson and Gould, and ofcourse, myself.
Sincerely,
Thomas 1. Novitsky, Ph.D.
President/CEO
o 1995, Associates of Cape Cod, Inc., Woods Hole, Massachusetts
Endotoxin
Limits
Michael E. Dawson, Ph.D.
It has been established that the
pyrogenic threshold for humans is
approximately five endotoxin units
(EU) per kilogram body weight (1,2).
This means that administration of
endotoxin concentrations of 5 EUlkg
or greater can be expected to elicit a
pyrogenic response. Consequently,
an endotoxin limit of 5 EUlkglhr has
been set for most injectable
(parenteral) products. An injectable
product for which this limit applies
cannot be sold if the endotoxin
concentration is such that a recipient
of the maximum dose would receive
this amount of endotoxin or more.
The endotoxin limit is represented
by the term K. The value of K is 5
EUlkglhr for injectables, other than
those administered intrathecally. For
these, the endotoxin limit is more
stringent and K= 0.2 EUlkglhr.
Given that the average human
weighs 70 kg, the maximum amount
ofendotoxin that can be received by a
patient being given a non-intrathecal
product should not exceed 350 EU
per hour (70 x 5 EUlkglhr).
However, the limit does not
account for a patient being given
several drugs and/or solutions at
All rights reserved
once, which is a common occurrence.
Fortunately, most drug products and
solutions contain considerably less
endotoxin than the allowable limit.
Many manufacturers set specifica-
tions that are tighter than the required
limit.
The calculation of endotoxin
limits for injectable drugs adminis-
tered per square meter is based on the
assumption that a typical adult has a
surface area of 1.8 square meters.
For drugs with a dose expressed per
kg, the whole body limit is 350 ED.
Thus, the endotoxin limit per square
meter is 350 EU/1.8 m2
= 194EU/m2
This is an absolute and is equivalent
to a value of 5 EU/kg for K for
products administered per kg. To
calculate the endotoxin limit of a
product with a dose expressed per
square meter, divide 194 EU/ m? by
the dose to give an endotoxin limit per
unit of product.
Endotoxin limits for radio-
pharmaceuticals are addressed in a
footnote at the end of Appendix E to
the FDA Guideline on the LAL Test
(3). For these productsK= 175 (EU)/
V (or 14(EU)N for intrathecals),
where V is the maximum (whole
body) dose in ml at expiration of the
product. The units (the EU given in
parentheses) are not specified in the
Guideline but must be included if the
units are to be expressed in EU/m!.
The USP limit for large volume
parenterals (LVPs) is 0.5 EU/ml and
is derived from a rabbit dose of10 ml/
kg for Pyrogen tests. A typical LVP
administered at 700 ml/hr also gives a
limit of 0.5 EU/m!. The USP
endotoxin limit for WFI and SWFI is
0.25 EU/m!. For medical devices,
the USP limit is 20 EU/device, and
2.15 EU/device for devices that
contact the cerebrospinal fluid. The
endotoxin limits for devices were
discussed in the September 1994
LAL UPDATE Vol. 13, Number 2, page 2
issue of the LAL UPDATE®
Generally, the aim of testing is to
insure that the sample under test
could not deliver more than 5 (or 0.2)
EU/kg/hr of endotoxin to a patient.
Thus, the endotoxin limit for a
specific product depends on the
maximum dose of product that a
patient might receive. The smaller
the dose of the product per kg, the
higher the endotoxin limit per unit
dose ofthe product.
This discussion of limits only
applies to release testing of finished
products. However, endotoxin limits
may be set for raw materials and in-
process samples.
Determining the Endotoxin Limit
ofa Product
The first step is to look up the
product in the FDA Guideline to see
if an endotoxin limit is listed in the
Appendix E. (The most recent
revision to Appendix E at this time is
dated July, 1994). If the product is
listed, check that the maximum dose
of the product is correct for your
product. If the dose is greater than
that given in the table, calculate the
limit as described below. It is a good
idea to calculate the limitas described
below anyway. There have been
mistakes in the Appendix in the past.
The 1987 Guideline states that the
dose used should be the rabbit dose
(as used in the USP Pyrogen Test) or
the maximum human dose, which-
ever is greater. Since 1987, the USP
has used only human doses to
calculate endotoxin limits and the
FDA has incorporated this into their
more recent revisions ofAppendix E.
The term M is used for the maximum
dose.
When calculating the limit for
drug products, if the dose is
expressed for whole (adult) body,
first divide it by 70 kg to give the dose
per kg. Then divide K (5 EU/kg, 0.2
EU/kg, 194 EU/m2
or 175 EU) by M
(or V) to give the endotoxin limit per
unit weight/volumelinternational
unit, etc.
Examples:
Calculation of the endotoxin limit
for a non-intrathecal, injectable
drug product:
Product A has a maximum human
(whole body) dose of 1.0 g
Dose per kg =
.Ls, = 0.0143 g/kg = 14.3 mg/kg
70 kg
Endotoxin limit =
K = 5 ED/kg = 0.35 ED/mg
M 14.3 mg/kg
Use the concentration of the product
(potency in final product) to convert
the endotoxin limit into EU/m!.
Thus, using the example above, if
the concentration of product in the
(presentation) container is 100 mg/
ml, or if bulk product is dissolved to
give 100 mg/m!:
Endotoxin limit =
0.35 EU/mg x 100 mg/ml = 35 ED/ml
Convert the limit to EU/ml
because these are the units of the
endotoxin standards in the LAL test
(as well as the limits for the sensitivity
of an LAL gel-clot reagent). This
gives an endotoxin limit for the
product so that it can be determined
whether the product passes or fails at
that limit. It is important to note that
the limit in EU/ml only applies to the
stated concentration ofproduct. Ifthe
concentration changes, the limit
changes.
The limits calculated above are
the maximum allowed. It may be
decided that tighter limits are
From left to right: Laurie Fife, Keith Richardson and Carmen Barillas
Meet Associates of Cape Cod, Inc.'s
Technical Services Department
desirable. Usually the limit is greater
than the sensitivity ofthe test method.
If the gel-clot method is used as a
pass/fail test, the product must be
diluted.
Calculation of the endotoxin limit
for a product with a dose
expressed per square meter:
For a product with a dose of I g/m?
and a potency of 50 mg/ml:
Endotoxin Limit =
194 ED/ m?= 194 ED/g = 0.194 ED/mg
1 g/m?
0.194 ED/mg x 50 mg/ml = 9.7 El.l/rnl
Calculation of an endotoxin limit
for a radio-pharmaceutical
product:
For a product with a (whole body)
dose at expiration of 7 ml:
Endotoxin Limit =
K 175 ED 25 ED/ml
V 7ml
Conclusion
A clear understanding of endotoxin
limits and how they are derived is of
critical importance to the release of
product by any LAL test method.
References:
1. EIin, R. J., S. M. Wolff, K. P. W. J. McAdam, L.
Chedid, and F. Oberling. 1981. Properties of
reference Escherichia coli endotoxin and its
phthalylated derivative in humans. J. Infect. Dis. 144:
329-336.
2. Hochstein, H. D., E. A. Fitzgerald, F. G.
McMachon, and R. Vargas. 1994. Properties of US
Standard Endotoxin (EC-5) inhuman male volunteers.
Journal of Endotoxin Research. 1:52-56.
3. Guideline on Validation of the Limulus
Amebocyte Test as an End-product Endotoxin
Test for Human and Animal Parenteral Drugs,
Biological Products, and Medical Devices. U.S.
Department of Health and Human Services, Public
Health Services, Food and Drug Administration,
December 1987.
LAL UPDATE Vol. 13, Number 2, page 3
With the continuing expansion ofour
business, we now have three Technical
Services Representatives to answer your
LAL-related questions. As in the past,
all calls are answered immediately by
our Technical Services Department. The
department includes: Laurie Fife, Se-
nior Technical Services Specialist,
Keith Richardson, Technical Analyst
and Carmen Barillas, Technical Ser-
vice Representative.
Laurie joined ACC in 1993 after
doing research for six years in the areas
ofcell/molecularbiology and biochemis-
try. For two years before moving to Cape
Cod, Laurie was a Scientific Liaison at
Organogenesis, Inc.
At ACC, Laurie provides technical
assistance and participates in the training
courses. She specializes in the chro-
mogenic LAL method. She has a BS
degree in Animal Science from the
University of Vermont.
Keith has been an employee of
Associates of Cape Cod, Inc. for more
than five years and has experience in
many facets of LAL technology, from
hemolymph collection to use of our final
products. He is responsible for all
aspects ofturbidimetric LAL testing, and
is the technical support person for the
LAL-5000 and Pyros™ software. As
our turbidimetric specialist, Keith par-
ticipates in ACC training courses. Keith
has a BS degree in Biology and Marine
Sciences from Southeastern Massachu-
setts University.
Carmen has an MS in Biology from
Worcester Polytechnic Institute and did
her thesis work in the Biochemistry
Department at the University of Massa-
chusetts Medical Center. She was Senior
Research Associate at Genica Pharma-
ceuticals Corporation, where she did
product development and research in
molecular biology for two years before
joining ACC in 1994. Carmen is a native
of Guatemala, Central America, and is
fluent in both Spanish and English. The
combination ofher technical background
and language skills makes Carmen a
welcome addition to our technical
department. She also participates in the
training courses offered by ACe.
For expert technical help, regardless of
the brand of LAL Limulus Amebocyte
Lysate you use, call 800-848-3248.

More Related Content

Similar to LAL_Vol.13No.2.pdf

Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
PerkinElmer, Inc.
 
Research Paper 2012
Research Paper 2012Research Paper 2012
Research Paper 2012
James Vasquez
 
Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...
Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...
Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...
PRASANTAKUMARMOHAPAT3
 
f) Blueridge Poster Presentation
f) Blueridge Poster Presentationf) Blueridge Poster Presentation
f) Blueridge Poster Presentation
Chelsea Herron
 
Impact_of_di-_2-ethylhexyl_phthalate_on
Impact_of_di-_2-ethylhexyl_phthalate_onImpact_of_di-_2-ethylhexyl_phthalate_on
Impact_of_di-_2-ethylhexyl_phthalate_on
Kalaivani Manokaran
 
Speer survantacurosurf
Speer  survantacurosurfSpeer  survantacurosurf
Speer survantacurosurf
Mauricio Piñeros
 
The safety aspects of food additives
The safety aspects of food additivesThe safety aspects of food additives
The safety aspects of food additives
Aleppo University
 
Parenterals-PPT.pptx
Parenterals-PPT.pptxParenterals-PPT.pptx
Parenterals-PPT.pptx
Rajakumari Rajendran
 
The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...
The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...
The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...
CorDynamics
 
Jairam
JairamJairam
Jairam
jaipharma76
 
Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...
Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...
Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...
European Sustainable Phosphorus Platform
 
34590 94-8
34590 94-834590 94-8
34590 94-8
Ti Na Đàm
 
Short courses in food safety risk assessment
Short courses in food safety risk assessmentShort courses in food safety risk assessment
Short courses in food safety risk assessment
EFSA EU
 
Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...
Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...
Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...
IOSR Journals
 
Eribis pharmaceuticals AB
Eribis pharmaceuticals ABEribis pharmaceuticals AB
Eribis pharmaceuticals AB
Erik Bissessar
 
Get it Here - Cruelty Free Cosmetics
Get it Here - Cruelty Free Cosmetics Get it Here - Cruelty Free Cosmetics
Get it Here - Cruelty Free Cosmetics
v2zq
 
Toxicology endpoints
Toxicology endpointsToxicology endpoints
Toxicology endpoints
ArreyettaBawakAugust
 
Pyrogen and its various test
Pyrogen and its various testPyrogen and its various test
Pyrogen and its various test
Prachi Barbhaiya
 
Copd
CopdCopd
The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...
The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...
The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...
PerkinElmer, Inc.
 

Similar to LAL_Vol.13No.2.pdf (20)

Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
Analysis of Phenolic Antioxidants in Edible Oil/Shortening Using the PerkinEl...
 
Research Paper 2012
Research Paper 2012Research Paper 2012
Research Paper 2012
 
Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...
Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...
Formulation and Evaluation of Sublingual Tablet of Enalapril Maleate By 32 Fu...
 
f) Blueridge Poster Presentation
f) Blueridge Poster Presentationf) Blueridge Poster Presentation
f) Blueridge Poster Presentation
 
Impact_of_di-_2-ethylhexyl_phthalate_on
Impact_of_di-_2-ethylhexyl_phthalate_onImpact_of_di-_2-ethylhexyl_phthalate_on
Impact_of_di-_2-ethylhexyl_phthalate_on
 
Speer survantacurosurf
Speer  survantacurosurfSpeer  survantacurosurf
Speer survantacurosurf
 
The safety aspects of food additives
The safety aspects of food additivesThe safety aspects of food additives
The safety aspects of food additives
 
Parenterals-PPT.pptx
Parenterals-PPT.pptxParenterals-PPT.pptx
Parenterals-PPT.pptx
 
The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...
The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...
The Differential Effect of Nembutal and Ketamine/Xylazine Anesthetic on QT In...
 
Jairam
JairamJairam
Jairam
 
Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...
Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...
Pharmaceuticals in Our Environment: Current Challenges and Future Outlook - F...
 
34590 94-8
34590 94-834590 94-8
34590 94-8
 
Short courses in food safety risk assessment
Short courses in food safety risk assessmentShort courses in food safety risk assessment
Short courses in food safety risk assessment
 
Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...
Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...
Analysis of Organophosphate Pesticides Residue on Crops in Abakaliki, Ebonyi ...
 
Eribis pharmaceuticals AB
Eribis pharmaceuticals ABEribis pharmaceuticals AB
Eribis pharmaceuticals AB
 
Get it Here - Cruelty Free Cosmetics
Get it Here - Cruelty Free Cosmetics Get it Here - Cruelty Free Cosmetics
Get it Here - Cruelty Free Cosmetics
 
Toxicology endpoints
Toxicology endpointsToxicology endpoints
Toxicology endpoints
 
Pyrogen and its various test
Pyrogen and its various testPyrogen and its various test
Pyrogen and its various test
 
Copd
CopdCopd
Copd
 
The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...
The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...
The Analysis of SunscreenActive Ingredients and Parabens in Lotions and Lip B...
 

Recently uploaded

Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and SynonymsGiloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Planet Ayurveda
 
Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1 Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1
Jyoti Bhaghasra
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
Gokuldas Hospital
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
ayushrajshrivastava7
 
Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"
AlexandraDiaz101
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
MuskanShingari
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
TigistuMelak
 
biomechanics of running. Dr.dhwani.pptx
biomechanics of running.   Dr.dhwani.pptxbiomechanics of running.   Dr.dhwani.pptx
biomechanics of running. Dr.dhwani.pptx
Dr. Dhwani kawedia
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Jim Jacob Roy
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
shruti jagirdar
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Dr. Deepika's Homeopathy - Gaur City
 
District Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PGs in India.pptxDistrict Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PGs in India.pptx
CommunityMedicine46
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
Bhavyakelawadiya
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
Gokuldas Hospital
 
All about shoulder Joint ..
All about shoulder Joint .. All about shoulder Joint ..
All about shoulder Joint ..
Aswan University Hospital
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
Dr. Sumit KUMAR
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
MuhammadMuneer49
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 

Recently uploaded (20)

Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and SynonymsGiloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
 
Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1 Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
 
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
 
Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"Debunking Nutrition Myths: Separating Fact from Fiction"
Debunking Nutrition Myths: Separating Fact from Fiction"
 
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)
 
13. PROM premature rupture of membranes
13.  PROM premature rupture of membranes13.  PROM premature rupture of membranes
13. PROM premature rupture of membranes
 
biomechanics of running. Dr.dhwani.pptx
biomechanics of running.   Dr.dhwani.pptxbiomechanics of running.   Dr.dhwani.pptx
biomechanics of running. Dr.dhwani.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
 
District Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PGs in India.pptxDistrict Residency Programme (DRP) for PGs in India.pptx
District Residency Programme (DRP) for PGs in India.pptx
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
 
All about shoulder Joint ..
All about shoulder Joint .. All about shoulder Joint ..
All about shoulder Joint ..
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 

LAL_Vol.13No.2.pdf

  • 1. In this issue: Endotoxin Limits Technical Services Department Calendar Volume 13, No.2 pfiJLAL UPDATE® June 1995 Dear LAL User, There are now definite signs that summer will soon arrive on Cape Cod. The horseshoe crabs have appeared once again in the shallow bays in preparation for spawning and our laboratory is bursting with activity. Although the amount ofour harvestfrom season to season is difficult to predict, the last two years have seen recordyields ofLAL and we hope for a repeat this year. Even with increased sales, these good harvests have resulted in an excellent inventory ofPyrotell'" (all sensitivities), Pyrotell'"-T, and Pyrochrome" For our European customers, the changeoverfrom afragmented distribution system to direct supply and service from Associates of Cape Cod International, Inc. is complete. Our two European offices are located in Walldorf(near Frankfurt) Germany, and Liverpool, England. Our general managers, Dr. Peter Weidner (ACCI-Europe in Germany), and Tony Coyle (ACCI-UK) have extensive experience with all aspects ofLAL and endotoxin testing. In addition to our expanded technical services, ACCI-Europe can provide multilingual help for our clients in France, Italy, and Spain. The Tyros™ for Windows" software for the LAL-5000 is now firmly established in the marketplace. Ifyou are using the LAL-5000 and have not yet switched to Tyros™, I strongly urge you to consider doing so. It is much easier andfaster to use and has a host ofadvancedfeatures. As you can see, it is not all vacation and retirement on Cape Cod. Even so, please feel free to make our summer even busier! Our technical service team, Laurie, Keith, and Carmen are ready to answer your technical questions, as are other personnel, including Drs. Dawson and Gould, and ofcourse, myself. Sincerely, Thomas 1. Novitsky, Ph.D. President/CEO o 1995, Associates of Cape Cod, Inc., Woods Hole, Massachusetts Endotoxin Limits Michael E. Dawson, Ph.D. It has been established that the pyrogenic threshold for humans is approximately five endotoxin units (EU) per kilogram body weight (1,2). This means that administration of endotoxin concentrations of 5 EUlkg or greater can be expected to elicit a pyrogenic response. Consequently, an endotoxin limit of 5 EUlkglhr has been set for most injectable (parenteral) products. An injectable product for which this limit applies cannot be sold if the endotoxin concentration is such that a recipient of the maximum dose would receive this amount of endotoxin or more. The endotoxin limit is represented by the term K. The value of K is 5 EUlkglhr for injectables, other than those administered intrathecally. For these, the endotoxin limit is more stringent and K= 0.2 EUlkglhr. Given that the average human weighs 70 kg, the maximum amount ofendotoxin that can be received by a patient being given a non-intrathecal product should not exceed 350 EU per hour (70 x 5 EUlkglhr). However, the limit does not account for a patient being given several drugs and/or solutions at All rights reserved
  • 2. once, which is a common occurrence. Fortunately, most drug products and solutions contain considerably less endotoxin than the allowable limit. Many manufacturers set specifica- tions that are tighter than the required limit. The calculation of endotoxin limits for injectable drugs adminis- tered per square meter is based on the assumption that a typical adult has a surface area of 1.8 square meters. For drugs with a dose expressed per kg, the whole body limit is 350 ED. Thus, the endotoxin limit per square meter is 350 EU/1.8 m2 = 194EU/m2 This is an absolute and is equivalent to a value of 5 EU/kg for K for products administered per kg. To calculate the endotoxin limit of a product with a dose expressed per square meter, divide 194 EU/ m? by the dose to give an endotoxin limit per unit of product. Endotoxin limits for radio- pharmaceuticals are addressed in a footnote at the end of Appendix E to the FDA Guideline on the LAL Test (3). For these productsK= 175 (EU)/ V (or 14(EU)N for intrathecals), where V is the maximum (whole body) dose in ml at expiration of the product. The units (the EU given in parentheses) are not specified in the Guideline but must be included if the units are to be expressed in EU/m!. The USP limit for large volume parenterals (LVPs) is 0.5 EU/ml and is derived from a rabbit dose of10 ml/ kg for Pyrogen tests. A typical LVP administered at 700 ml/hr also gives a limit of 0.5 EU/m!. The USP endotoxin limit for WFI and SWFI is 0.25 EU/m!. For medical devices, the USP limit is 20 EU/device, and 2.15 EU/device for devices that contact the cerebrospinal fluid. The endotoxin limits for devices were discussed in the September 1994 LAL UPDATE Vol. 13, Number 2, page 2 issue of the LAL UPDATE® Generally, the aim of testing is to insure that the sample under test could not deliver more than 5 (or 0.2) EU/kg/hr of endotoxin to a patient. Thus, the endotoxin limit for a specific product depends on the maximum dose of product that a patient might receive. The smaller the dose of the product per kg, the higher the endotoxin limit per unit dose ofthe product. This discussion of limits only applies to release testing of finished products. However, endotoxin limits may be set for raw materials and in- process samples. Determining the Endotoxin Limit ofa Product The first step is to look up the product in the FDA Guideline to see if an endotoxin limit is listed in the Appendix E. (The most recent revision to Appendix E at this time is dated July, 1994). If the product is listed, check that the maximum dose of the product is correct for your product. If the dose is greater than that given in the table, calculate the limit as described below. It is a good idea to calculate the limitas described below anyway. There have been mistakes in the Appendix in the past. The 1987 Guideline states that the dose used should be the rabbit dose (as used in the USP Pyrogen Test) or the maximum human dose, which- ever is greater. Since 1987, the USP has used only human doses to calculate endotoxin limits and the FDA has incorporated this into their more recent revisions ofAppendix E. The term M is used for the maximum dose. When calculating the limit for drug products, if the dose is expressed for whole (adult) body, first divide it by 70 kg to give the dose per kg. Then divide K (5 EU/kg, 0.2 EU/kg, 194 EU/m2 or 175 EU) by M (or V) to give the endotoxin limit per unit weight/volumelinternational unit, etc. Examples: Calculation of the endotoxin limit for a non-intrathecal, injectable drug product: Product A has a maximum human (whole body) dose of 1.0 g Dose per kg = .Ls, = 0.0143 g/kg = 14.3 mg/kg 70 kg Endotoxin limit = K = 5 ED/kg = 0.35 ED/mg M 14.3 mg/kg Use the concentration of the product (potency in final product) to convert the endotoxin limit into EU/m!. Thus, using the example above, if the concentration of product in the (presentation) container is 100 mg/ ml, or if bulk product is dissolved to give 100 mg/m!: Endotoxin limit = 0.35 EU/mg x 100 mg/ml = 35 ED/ml Convert the limit to EU/ml because these are the units of the endotoxin standards in the LAL test (as well as the limits for the sensitivity of an LAL gel-clot reagent). This gives an endotoxin limit for the product so that it can be determined whether the product passes or fails at that limit. It is important to note that the limit in EU/ml only applies to the stated concentration ofproduct. Ifthe concentration changes, the limit changes. The limits calculated above are the maximum allowed. It may be decided that tighter limits are
  • 3. From left to right: Laurie Fife, Keith Richardson and Carmen Barillas Meet Associates of Cape Cod, Inc.'s Technical Services Department desirable. Usually the limit is greater than the sensitivity ofthe test method. If the gel-clot method is used as a pass/fail test, the product must be diluted. Calculation of the endotoxin limit for a product with a dose expressed per square meter: For a product with a dose of I g/m? and a potency of 50 mg/ml: Endotoxin Limit = 194 ED/ m?= 194 ED/g = 0.194 ED/mg 1 g/m? 0.194 ED/mg x 50 mg/ml = 9.7 El.l/rnl Calculation of an endotoxin limit for a radio-pharmaceutical product: For a product with a (whole body) dose at expiration of 7 ml: Endotoxin Limit = K 175 ED 25 ED/ml V 7ml Conclusion A clear understanding of endotoxin limits and how they are derived is of critical importance to the release of product by any LAL test method. References: 1. EIin, R. J., S. M. Wolff, K. P. W. J. McAdam, L. Chedid, and F. Oberling. 1981. Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J. Infect. Dis. 144: 329-336. 2. Hochstein, H. D., E. A. Fitzgerald, F. G. McMachon, and R. Vargas. 1994. Properties of US Standard Endotoxin (EC-5) inhuman male volunteers. Journal of Endotoxin Research. 1:52-56. 3. Guideline on Validation of the Limulus Amebocyte Test as an End-product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices. U.S. Department of Health and Human Services, Public Health Services, Food and Drug Administration, December 1987. LAL UPDATE Vol. 13, Number 2, page 3 With the continuing expansion ofour business, we now have three Technical Services Representatives to answer your LAL-related questions. As in the past, all calls are answered immediately by our Technical Services Department. The department includes: Laurie Fife, Se- nior Technical Services Specialist, Keith Richardson, Technical Analyst and Carmen Barillas, Technical Ser- vice Representative. Laurie joined ACC in 1993 after doing research for six years in the areas ofcell/molecularbiology and biochemis- try. For two years before moving to Cape Cod, Laurie was a Scientific Liaison at Organogenesis, Inc. At ACC, Laurie provides technical assistance and participates in the training courses. She specializes in the chro- mogenic LAL method. She has a BS degree in Animal Science from the University of Vermont. Keith has been an employee of Associates of Cape Cod, Inc. for more than five years and has experience in many facets of LAL technology, from hemolymph collection to use of our final products. He is responsible for all aspects ofturbidimetric LAL testing, and is the technical support person for the LAL-5000 and Pyros™ software. As our turbidimetric specialist, Keith par- ticipates in ACC training courses. Keith has a BS degree in Biology and Marine Sciences from Southeastern Massachu- setts University. Carmen has an MS in Biology from Worcester Polytechnic Institute and did her thesis work in the Biochemistry Department at the University of Massa- chusetts Medical Center. She was Senior Research Associate at Genica Pharma- ceuticals Corporation, where she did product development and research in molecular biology for two years before joining ACC in 1994. Carmen is a native of Guatemala, Central America, and is fluent in both Spanish and English. The combination ofher technical background and language skills makes Carmen a welcome addition to our technical department. She also participates in the training courses offered by ACe. For expert technical help, regardless of the brand of LAL Limulus Amebocyte Lysate you use, call 800-848-3248.